HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Trading 01-13 14:38:20

68.250

+3.650

+5.65%

High71.450	Low64.100	Vol863.00K
Open64.100	D1 Closing64.600	Amplitude11.38%
Mkt Cap37.09B	Tradable Cap11.15B	Total Shares543.49M
T/O60.02M	T/O Rate0.53%	Tradable Shares163.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":68.25,"timestamp":1768286293165,"preClose":64.6,"halted":0,"volume":863000,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6884251106466603,"marketStatus":"Trading","change":3.65,"latestTime":"01-13 14:38:20","open":64.1,"high":71.45,"low":64.1,"amount":60024992,"amplitude":0.113777,"askPrice":68.5,"askSize":100,"bidPrice":68.25,"bidSize":600,"shortable":3,"etf":0,"ttmEps":1.6962989653429825,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768291800000},"marketStatusCode":2,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":64.6,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":1.557288,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1146080787","title":"Hong Kong Stock Movement | HENLIUS (02696) Surges Over 8% Again, Broad-Spectrum Anti-Tumor PD-L1 ADC HLX43 Phase II Data for End-Line Esophageal Squamous Cell Carcinoma First Released","url":"https://stock-news.laohu8.com/highlight/detail?id=1146080787","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146080787?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:16","pubTimestamp":1768270598,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) surged over 8% again, with an increase of 8.05% at the time of writing, reaching HK$69.8, and a turnover of HK$18.6408 million. On January 9th, at the 2026 American Society of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","PD","02696","BK4231","HK0000165453.HKD","LU1169590202.USD","HK0000320264.USD","BK4080","BK1161","HK0000306701.USD","HK0000306685.HKD","BK4023","ADC","LU1169589451.USD"],"gpt_icon":0},{"id":"1118913475","title":"HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1118913475","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118913475?lang=en_us&edition=fundamental","pubTime":"2026-01-08 11:24","pubTimestamp":1767842659,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million. On the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4080","HK0000165453.HKD","BK4231","PD","BK1161","LU1169590202.USD","02696","LU1169589451.USD","ADC"],"gpt_icon":0},{"id":"2601740382","title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After HLX37 Enters Phase 1 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601740382","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601740382?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:46","pubTimestamp":1767807982,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) has dosed the first patient in its phase 1 trial of HLX37, a bispecific antibody that targets PD-L1 and VEGF in advanced or metastatic solid tumours in Mainland China.\nSee our latest analysis for Shanghai Henlius Biotech.\nThe HLX37 trial update comes after a mixed stretch for the stock, with a 1-day share price return of 2.00% and a 7-day share price return of 11.92% but a 90-day share price return of 15.71%. However, the 1-year total shareholder return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02696","DCF","HK0000165453.HKD"],"gpt_icon":0},{"id":"1165136813","title":"HENLIUS (02696.HK) Surges Nearly 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165136813","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165136813?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:30","pubTimestamp":1767583835,"startTime":"0","endTime":"0","summary":"HENLIUS (02696.HK) is currently up nearly 9%, having gained 8.62% to reach HKD 63.65 at the time of writing, with a trading volume of HKD 29.04 million.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1178651656","title":"Hong Kong Stock Movement | HENLIUS (02696) Surges Nearly 9% as IND Applications for Three Innovative Solid Tumor Drugs Are Accepted Concurrently","url":"https://stock-news.laohu8.com/highlight/detail?id=1178651656","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178651656?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:06","pubTimestamp":1767582385,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) is currently up nearly 9%. As of the time of writing, the stock has risen 8.62% to HK$63.65, with a turnover of HK$29.04 million. On December 30, HENLIUS announced that the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","IND","06978","02696","BK1161","HK0000165453.HKD","BK1574"],"gpt_icon":0},{"id":"1119808356","title":"Singapore's GIC Boosts Stake in Henlius with 177,000 Shares at HK$56.76 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1119808356","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119808356?lang=en_us&edition=fundamental","pubTime":"2026-01-04 09:50","pubTimestamp":1767491444,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on December 30, Singapore's Government Investment Corporation (GIC) increased its holding in Henlius (02696) by 177,000 shares. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"1154328023","title":"Singapore's GIC Increases Stake in HENLIUS (02696) by 177,000 Shares at HK$56.76 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1154328023","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154328023?lang=en_us&edition=fundamental","pubTime":"2026-01-02 18:28","pubTimestamp":1767349697,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Singapore's Government Investment Corporation (GIC) increased its stake in HENLIUS (02696) by 177,000 shares on December 30, at a price...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2595786367","title":"Shanghai Henlius Biotech Inc. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786367","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595786367?lang=en_us&edition=fundamental","pubTime":"2025-12-31 18:00","pubTimestamp":1767175247,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. held its fourth extraordinary general meeting on December 31, 2025. The proposal to approve the Sinopharm Distribution Framework Agreement  and the transactions contemplated under it, including the relevant annual caps, was approved by shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL5WXRy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD","00656","BK1230"],"gpt_icon":0},{"id":"2595781783","title":"Henlius Biotech Doses First Patient in Phase 1 Trial of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2595781783","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595781783?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:45","pubTimestamp":1767005131,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) said the first patient has been dosed in a phase 1 clinical study of HLX37, according to a Monday Hong Kong bourse filing.The trial is studying the use of the drug in patients with advanced/metastatic solid tumors in the Chinese Mainland.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696","HK0000165453.HKD"],"gpt_icon":0},{"id":"2593505413","title":"Henlius CEO to Deliver Keynote at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2593505413","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593505413?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:54","pubTimestamp":1766498040,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via PR Newswire  on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL1zgTt3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","00656","BK1230","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2593312312","title":"Shanghai Henlius Biotech (SEHK:2696) Valuation Check After US FDA IND Approval for HLX18 Biosimilar Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593312312","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593312312?lang=en_us&edition=fundamental","pubTime":"2025-12-21 09:27","pubTimestamp":1766280437,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors.\nSee our latest analysis for Shanghai Henlius Biotech.\nThat HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-us-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-valuation-check-after-us-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","02696","HK0000165453.HKD","IND","BK1161"],"gpt_icon":0},{"id":"2592161786","title":"Henlius Biotech Gets US FDA Nod to Conduct Trial of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592161786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592161786?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:31","pubTimestamp":1766147517,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech's  investigational new drug application for the phase 1 clinical trial of HLX18 was approved by the US Food and Drug Administration, a Friday Hong Kong bourse filing said.The firm intends to begin US trials of the drug, which has been developed to treat multiple solid tumors, when certain conditions are met.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"1129223645","title":"HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX18, a Nivolumab Biosimilar, for Treatment of Various Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1129223645","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129223645?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:08","pubTimestamp":1766135300,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Phase 1 clinical trials of HLX18, a self-developed nivolumab...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2592527431","title":"FDA Approves Shanghai Henlius Biotech's IND Application for Nivolumab Biosimilar HLX18 Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592527431","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592527431?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:03","pubTimestamp":1766135022,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its investigational new drug application for a phase 1 clinical trial of HLX18, a nivolumab biosimilar , has been approved by the United States Food and Drug Administration . HLX18 is independently developed by Henlius for the treatment of multiple solid tumors. The company plans to initiate the clinical trial in the United States when conditions permit. No other organizations are mentioned as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 19, 2025, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL4mw4c6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1161","BK1230","00656","02696"],"gpt_icon":0},{"id":"2592527381","title":"Shanghai Henlius Biotech Inc - Phase 1 Clinical Trial of Nivolumab Biosimilar Hlx18 Approved by United States FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592527381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592527381?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:01","pubTimestamp":1766134868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2590057213","title":"BRIEF-Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590057213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590057213?lang=en_us&edition=fundamental","pubTime":"2025-12-12 17:40","pubTimestamp":1765532452,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Henlius Biotech Says NDA For Hansizhuang Granted Priority Review By NMPADec 12 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK:NDA FOR HANSIZHUANG GRANTED PRIORITY REVIEW BY NMPAFurther company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1161","02696"],"gpt_icon":0},{"id":"1158714296","title":"HENLIUS (02696): NDA for Hansizhuang® Combined with Chemotherapy in Gastric Cancer Neoadjuvant/Adjuvant Therapy Accepted by NMPA and Included in Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1158714296","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158714296?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:56","pubTimestamp":1765529788,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the New Drug Application (NDA) for its self-developed Hansizhuang® (serplulimab injection) combined with platinum-based chemotherapy as neoadjuvant and adjuvant therapy...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2590719945","title":"Henlius Biotech's Serplulimab NDA for Gastric Cancer Combo Granted Priority Review by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590719945","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590719945?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:48","pubTimestamp":1765529285,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech Inc. announced that its New Drug Application  for HANSIZHUANG  in combination with chemotherapy for neo-/adjuvant treatment of gastric cancer has been accepted by the National Medical Products Administration  of China and has been granted priority review. This regulatory milestone follows the achievement of the primary endpoint in a Phase 3 clinical trial in mainland China. No other organizations were mentioned as recipients of this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1YbQhN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1230","02696","HK0000165453.HKD","00656","BK1161"],"gpt_icon":0},{"id":"2590457193","title":"Shanghai Henlius Biotech Inc - Nda for Hansizhuang Granted Priority Review by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590457193?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:46","pubTimestamp":1765529211,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"1172386204","title":"HENLIUS (02696): Phase 2/3 Clinical Trial Applications for HLX22 Combined with HLX87 in HER2-Positive Breast Cancer First-Line Treatment and Neoadjuvant Therapy Approved by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1172386204","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172386204?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:24","pubTimestamp":1765272265,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) announced that the National Medical Products Administration (NMPA) has approved the Phase 2/3 clinical trial applications for HLX22 (a recombinant humanized anti-HER2 monoclonal...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","BK4190","BK1161","BC","HK0000165453.HKD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0336},{"period":"1month","weight":-0.0031},{"period":"3month","weight":-0.03},{"period":"6month","weight":0.083},{"period":"1year","weight":1.7845},{"period":"ytd","weight":0.1323}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0243},{"period":"3month","weight":0.0459},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.3957},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.026114},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}